相似文献
1
Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain.
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):85-87. Epub 2017 Sep 28.
2
Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?
Curr Opin Rheumatol. 2017 Jan;29(1):110-118. doi: 10.1097/BOR.0000000000000354.
3
Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis.
Osteoarthritis Cartilage. 2015 Jun;23(6):925-32. doi: 10.1016/j.joca.2015.02.002. Epub 2015 Feb 9.
4
A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.
Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S8-17. doi: 10.1016/j.joca.2014.10.003.
5
Monoclonal antibodies for the treatment of osteoarthritis.
Expert Opin Biol Ther. 2016 Dec;16(12):1529-1540. doi: 10.1080/14712598.2016.1229774. Epub 2016 Sep 11.
6
Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?
Drugs. 2014 Apr;74(6):619-26. doi: 10.1007/s40265-014-0208-6.
7
Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
Drugs. 2017 Sep;77(13):1377-1387. doi: 10.1007/s40265-017-0781-6.
8
Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis.
Ann Rheum Dis. 2019 May;78(5):672-675. doi: 10.1136/annrheumdis-2018-214489. Epub 2019 Mar 12.
9
[The fine line between innovation and risk : Is anti-NGF a pain medication of the future?].
Schmerz. 2010 Dec;24(6):559-60. doi: 10.1007/s00482-010-0993-0.
10
The current status of imaging in anti-NGF clinical trials.
Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S3-7. doi: 10.1016/j.joca.2014.09.002.
引用本文的文献
1
Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip.
BMC Musculoskelet Disord. 2025 Feb 25;26(1):192. doi: 10.1186/s12891-025-08402-8.
2
A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip.
Osteoarthr Cartil Open. 2024 Oct 22;6(4):100533. doi: 10.1016/j.ocarto.2024.100533. eCollection 2024 Dec.
3
Emerging evidence of artemin/GFRα3 signaling in musculoskeletal pain.
Osteoarthritis Cartilage. 2025 Feb;33(2):196-206. doi: 10.1016/j.joca.2024.09.010. Epub 2024 Oct 5.
4
Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With Osteoarthritis.
Osteoarthr Imaging. 2022 Sep-Dec;2(3-4). doi: 10.1016/j.ostima.2022.100082. Epub 2022 Nov 15.
5
Anti-NGF treatment worsens subchondral bone and cartilage measures while improving symptoms in floor-housed rabbits with osteoarthritis.
Front Physiol. 2023 Jun 26;14:1201328. doi: 10.3389/fphys.2023.1201328. eCollection 2023.
6
Role of imaging for eligibility and safety of a-NGF clinical trials.
Ther Adv Musculoskelet Dis. 2023 May 29;15:1759720X231171768. doi: 10.1177/1759720X231171768. eCollection 2023.
7
Targeting Neuroinflammation in Osteoarthritis with Intra-Articular Adelmidrol.
Biomolecules. 2022 Oct 11;12(10):1453. doi: 10.3390/biom12101453.
8
The Effectiveness of Duloxetine for Knee Osteoarthritis: An Overview of Systematic Reviews.
Front Physiol. 2022 Jun 7;13:906597. doi: 10.3389/fphys.2022.906597. eCollection 2022.
9
Painful Truth: The Need to Re-Center Chronic Pain on the Functional Role of Pain.
J Pain Res. 2022 Feb 16;15:497-512. doi: 10.2147/JPR.S347780. eCollection 2022.
10
The EANM guideline for radiosynoviorthesis.
Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):681-708. doi: 10.1007/s00259-021-05541-7. Epub 2021 Oct 20.
本文引用的文献
1
Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessment.
Semin Arthritis Rheum. 2017 Dec;47(3):323-330. doi: 10.1016/j.semarthrit.2017.05.008. Epub 2017 May 20.
2
Nerve Growth Factor and Pain Mechanisms.
Annu Rev Neurosci. 2017 Jul 25;40:307-325. doi: 10.1146/annurev-neuro-072116-031121. Epub 2017 Apr 24.
3
Osteoarthritis in 2016: Anti-NGF treatments for pain - two steps forward, one step back?
Nat Rev Rheumatol. 2017 Jan 25;13(2):76-78. doi: 10.1038/nrrheum.2016.224.
4
Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.
Pain Med. 2017 Feb 1;18(2):374-385. doi: 10.1093/pm/pnw262.
5
Tanezumab in the treatment of chronic musculoskeletal conditions.
Expert Opin Biol Ther. 2017 Feb;17(2):245-254. doi: 10.1080/14712598.2017.1271873. Epub 2016 Dec 25.
6
Emerging Targets for the Management of Osteoarthritis Pain.
Curr Osteoporos Rep. 2016 Dec;14(6):260-268. doi: 10.1007/s11914-016-0326-z.
7
Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?
Curr Opin Rheumatol. 2017 Jan;29(1):110-118. doi: 10.1097/BOR.0000000000000354.
8
Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis.
PLoS One. 2016 Jun 13;11(6):e0157105. doi: 10.1371/journal.pone.0157105. eCollection 2016.
9
Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration.
Osteoarthritis Cartilage. 2016 May;24(5):776-85. doi: 10.1016/j.joca.2015.12.011. Epub 2015 Dec 31.
10
When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.
Arthritis Rheumatol. 2016 Feb;68(2):382-91. doi: 10.1002/art.39492.
Zotero 插件